In a roundup of scientific studies on the novel coronavirus, new findings shed light on why chronic lung diseases that block the airways increase patients’ risks for severe Covid-19 and researchers say the blood disorder anemia should probably be added to the list of risk factors for poorer Covid-19 outcomes.
Members of the U.S. military who were vaccinated against Covid-19 showed higher-than-expected rates of heart inflammation, although the condition was still extremely rare, according to a study released on June 29.
Rare cases of heart inflammation in adolescents and young adults is likely linked to vaccination with the Pfizer/BioNTech and Moderna Covid-19 shots, a group of doctors advising the U.S. Centers for Disease Control and Prevention (CDC) said in a presentation released on June 23.
The U.S. Supreme Court on June 21 rejected a bid by an Amarin Corp. subsidiary to revive patents on the company’s heart drug Vascepa in a legal battle against generic drugmakers Hikma Pharmaceuticals Plc and Dr. Reddy’s Laboratories Ltd.
Europe’s drug regulator on June 11 identified another rare blood condition as a potential side effect of AstraZeneca’s Covid-19 vaccine and said it was looking into cases of heart inflammation after inoculation with all coronavirus shots.
Preliminary findings from two vaccine safety monitoring systems suggest a higher-than-expected number of cases of heart inflammation after the second dose of mRNA Covid-19 vaccines in young men, the U.S. Centers for Disease Control and Prevention (CDC) said on June 10.
Some teenagers and young adults who received Covid-19 vaccines experienced heart inflammation, a U.S. Centers for Disease Control and Prevention advisory group said, recommending further study of the rare condition.
Bristol Myers Squibb announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70th Annual Scientific Session with simultaneous publication in The Lancet.
Covid-19 heart changes raise death risk; virus may be lead killer of young adults during surges
American College of Cardiology, Antibiotic overuse, Coronavirus, Coronavirus Disease (COVID-19) Pandemic, COVID-19 Deaths, Data, Department of Health and Human Services (HHS), Doctors, Heart Injury, Hospitalized COVID-19 Patients, Outbreaks, R&D, U.S. Centers for Disease Control and Prevention, United States, Young AdultsIn a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for Covid-19, a new study may help identify which Covid-19 patients with signs of heart injury are at higher risk for death.
The U.S. Federal Circuit Court of Appeals in Washington, D.C. reinstated a 2017 jury verdict against Teva Pharmaceutical Industries, ordering the company to pay GlaxoSmithKline $235.5 million in a 13-year-old induced patent infringement case.